Statera Biopharma, Inc.
Statera Biopharma, Inc. (CBLI): 4 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.7 months
D/E -2.24 · 0% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Statera Biopharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$506K
Quarterly Burn
$802K
Runway
2.7 mo
Revenue
$670K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Statera Biopharma, Inc.'s pipeline?
Statera Biopharma, Inc. (CBLI) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Statera Biopharma, Inc.'s lead drug candidate?
Statera Biopharma, Inc.'s most advanced tracked candidate is entolimod (Phase 1) for Acute Radiation Syndrome (ARS) and Oncology.
What is Statera Biopharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Statera Biopharma, Inc. has approximately 2.7 months of cash runway.
Who is the CEO of Statera Biopharma, Inc.?
Michael K. Handley is the chief executive officer of Statera Biopharma, Inc. (CBLI).
Get the full picture on Statera Biopharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.